The new research report provides an in-depth study of the acute lymphocytic leukemia market and segmentation by route of administration (oral and parenteral), by type of molecules (biologics and small molecules), and by geography (the Americas, EMEA, and APAC). The report also presents a detailed analysis of the top companies operating in the market, including Amgen, Bristol-Myers Squibb, and Novartis.
Technavio’s market research analysts estimate the global acute lymphocytic leukemia market to grow at a CAGR of around 4% between 2015 and 2019. Some of the risk factors that have been identified with acute lymphocytic leukemia are exposure to chemicals such as benzene, radiation exposure, infection caused by Epstein-Barr virus and human T-cell lymphoma/leukemia virus-1. Though its actual cause is yet not known, however, it is also considered to be an inherited disease. Currently, the disease cannot be cured completely but the risk can be reduced by administering medication. The Americas dominate the global market for acute lymphocytic leukemia, accounting for around 49% of the total market share.
The new market research report from Technavio provides a breakdown and analysis of the acute lymphocytic leukemia segments by technology.
“The market is witnessing increase in awareness about the disease. The governments as well the NGOs across the world are making efforts to spread alertness about the acute myeloid leukemia among people. They are organizing seminars and webinars, conducting blogging competitions, sharing patients’ personal experiences, providing training and support to improve patients’ quality of life, aiding research initiatives, and helping the patients financially,” says Imran Mushtaq, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
The parenteral route of administration is preferred as the drugs delivered through this route are absorbed rapidly, and the onset of action is fast. The physicians are also opting out for this route when the immediate action of the drug is required. The drug is administered via intravenous, subcutaneous, intrathecal, or intramuscular routes. The parenteral route of drug administration entails stringent adherence to aseptic procedures.
The key vendors in the global acute lymphocytic leukemia market include Amgen, Bristol-Myers Squibb, and Novartis. The market is marked by the presence of both global and local drug manufacturers with varied product portfolios containing generic and off- label drugs as well as branded therapies. Besides, the high level of unmet medical need is expected to give a platform to the vendors to develop products to cater to relevant areas and enhance their market shares.
A more detailed analysis is available in the Technavio report, Global Acute Lymphocytic Leukemia Market 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other Related Reports:
